$NVAX; Novavax to Present COVID-19 Vaccine Candidate Progress in World Vaccine Congress Webinar Series May 11 2020 - 11:53AM GlobeNewswire Inc. Print
Novavax, Inc. (Nasdaq: NVAX), a late stage biotechnology company developing next-generation vaccines for serious infectious diseases, today announced that Gregory Glenn, M.D.,
President of Research and Development, will present progress of NVX-CoV2373, Novavax’ coronavirus vaccine candidate, on Wednesday,
May 13, 2020 as part of the World Vaccine Congress’ COVID-19 webinar series. Dr. Glenn joins a distinguished group of global public health, epidemiology, regulatory and industry leaders in sharing expertise and information related to the SARS-Cov-2 virus, as well as ongoing efforts to develop vaccines to address the global health pandemic.
Dr. Glenn’s presentation will be followed by a live Q&A discussion. Webinar details are as follows:
Topic: Recombinant Nanoparticle COVID-19 Vaccine: Platform Technology for Emerging Infectious Diseases (EID) Date and Time: Wednesday, May 13, 11:00 a.m. ET Moderator: Philip Krause, M.D., Deputy Director, OVRR, CBER, FDA
The webinar is free to attend. To register, please click here.
About NVX-CoV2373
NVX-CoV2373 is a vaccine candidate engineered from the genetic sequence of SARS-CoV-2, the virus that causes COVID-19 disease.
NVX-CoV2373 was created using Novavax’ recombinant nanoparticle technology to generate antigen derived from the coronavirus spike
(S) protein and contains Novavax’ patented saponin-based Matrix-M™ adjuvant to enhance the immune response and stimulate high levels of neutralizing antibodies.
In preclinical trials, NVX-CoV2373 demonstrated efficient binding with receptors targeted by the virus, a critical aspect for effective vaccine protection.
A Phase 1 clinical trial of NVX-CoV2373 will initiate in May 2020 with preliminary immunogenicity and safety results expected in July 2020.
The Coalition for Epidemic Preparedness Innovations (CEPI) has awarded an initial funding of $4 million to support Novavax’ NVX-CoV2373 efforts, with additional funding discussions ongoing.
About Novavax
Novavax, Inc. (Nasdaq:NVAX), is a late-stage biotechnology company that addresses urgent global health needs through the discovery, development, and commercialization of innovative vaccines. Novavax recently initiated development of NVX-CoV2373, its vaccine candidate against SARS-CoV-2,
the virus that causes COVID-19, with Phase 1 clinical trial results expected in July of 2020. NanoFlu™, its quadrivalent influenza nanoparticle vaccine, met all primary objectives in its pivotal Phase 3 clinical trial in older adults.
Both vaccine candidates incorporate Novavax’ proprietary saponin-based Matrix-M™ adjuvant in order to enhance the immune response and stimulate high levels of neutralizing antibodies.
Novavax is a leading innovator of recombinant nanoparticle vaccines;
its proprietary recombinant technology platform combines the power and speed of genetic engineering to efficiently produce highly immunogenic nanoparticles to address urgent global health needs.
For more information, visit http://www.novavax.com and connect with us on Twitter and LinkedIn.
News 
Market Data 
Discover 
